# Irinotecan Plus ICI D1694 in Treating Patients With Advanced Solid Tumors

> **NCT00002902** · PHASE1 · COMPLETED · sponsor: **Abramson Cancer Center at Penn Medicine**

## Conditions studied

- Unspecified Adult Solid Tumor, Protocol Specific

## Interventions

- **DRUG:** irinotecan hydrochloride
- **DRUG:** raltitrexed

## Key facts

- **NCT ID:** NCT00002902
- **Lead sponsor:** Abramson Cancer Center at Penn Medicine
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 1997-04
- **Primary completion:** —
- **Final completion:** —
- **Target enrollment:** — (—)
- **Last updated:** 2019-03-13

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00002902

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00002902, "Irinotecan Plus ICI D1694 in Treating Patients With Advanced Solid Tumors". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT00002902. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*